Catalyst Biosciences, Inc. (CBIO) Financial Statements (2023 and earlier)

Company Profile

Business Address 611 GATEWAY BLVD., SUITE 710
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:21,70046,90081,90076,900120,10032,400
Cash and cash equivalents21,66644,34730,36015,36931,21314,472
Short-term investments  2,50448,99461,49688,91417,971
Other undisclosed cash, cash equivalents, and short-term investments 34492,54635(27)(43)
Restricted cash and investments     505,333
Receivables  1,8183,31315,000 24
Other undisclosed current assets6,5062,7584,2974,1663,8411,352
Total current assets:28,20651,47689,51096,066123,99139,109
Noncurrent Assets
Operating lease, right-of-use asset 662,7441,8321,927
Property, plant and equipment 4970433304386276
Long-term investments and receivables   2,543   
Long-term investments   2,543   
Deposits noncurrent assets      128
Other noncurrent assets168472528257543 
Other undisclosed noncurrent assets      
Total noncurrent assets:2384,1865,3362,488929404
TOTAL ASSETS:28,44455,66294,84698,554124,92039,513
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,78611,95815,15013,4164,7863,435
Employee-related liabilities1,4672,4762,1061,4951,366
Accounts payable1946,4195,9314,2791,248747
Accrued liabilities11,5924,0726,7437,0312,0431,322
Deferred revenue  2301,98315,000
Debt    483 5,085
Deferred rent credit     15
Deferred revenue and credits219
Other undisclosed current liabilities 5,0381,977663   
Total current liabilities:16,82414,16517,79628,8994,8018,739
Noncurrent Liabilities
Long-term debt and lease obligation:  4089811,319  
Liabilities, other than long-term debt     174 
Deferred rent credit     174
Operating lease, liability  4089811,319
Other undisclosed noncurrent liabilities (408)(981)   
Total noncurrent liabilities: 4089811,319174 
Total liabilities:16,82414,57318,77730,2184,9758,739
Equity
Equity, attributable to parent(21,689)41,08976,06968,336119,94530,774
Common stock37312212126
Additional paid in capital389,210443,752390,803326,810323,279204,262
Accumulated other comprehensive income (loss)   534(4) 
Accumulated deficit(410,936)(402,694)(314,761)(258,520)(203,342)(173,494)
Other undisclosed equity33,309     
Total equity:11,62041,08976,06968,336119,94530,774
TOTAL LIABILITIES AND EQUITY:28,44455,66294,84698,554124,92039,513

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues  7,33820,948 61,018
Revenue, net1,018
Gross profit:  7,33820,948 61,018
Operating expenses(9,405)(95,232)(78,318)(57,277)(33,828)(22,840)
Other undisclosed operating income 794     
Operating loss:(8,611)(87,894)(57,370)(57,277)(33,822)(21,822)
Nonoperating income (expense) (87)659(39)1,654261
Other nonoperating income (expense) (87)659(39)1,650261
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(8,611)(87,981)(56,711)(57,316)(32,168)(21,561)
Other undisclosed income from continuing operations before income taxes717     
Loss from continuing operations before income taxes:(7,894)(87,981)(56,711)(57,316)(32,168)(21,561)
Income tax expense(348)     
Other undisclosed loss from continuing operations      
Loss from continuing operations:(8,242)(87,981)(56,711)(57,316)(32,168)(21,561)
Loss before gain (loss) on sale of properties:(87,981)(56,711)(57,316)(32,168)(21,561)
Other undisclosed net income (loss) 484702,1382,113 
Net loss:(8,242)(87,933)(56,241)(55,178)(30,055)(21,561)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(8,242)(87,933)(56,241)(55,178)(30,055)(21,561)
Preferred stock dividends and other adjustments      (3,951)
Net loss available to common stockholders, diluted:(8,242)(87,933)(56,241)(55,178)(30,055)(25,512)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(8,242)(87,933)(56,241)(55,178)(30,055)(21,561)
Comprehensive loss:(8,242)(87,933)(56,241)(55,178)(30,055)(21,561)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (5)(29)38(4)1
Comprehensive loss, net of tax, attributable to parent:(8,242)(87,938)(56,270)(55,140)(30,059)(21,560)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: